[View Larger Version of this Image]

Figure S2. Ag-SP therapy is effective in the absence of T reg cells. NOD BDC2.5 CD4⁺CD25^- (T reg cell-depleted) pathogenic T cells were transferred to NOD.TCRα KO T reg cell-deficient hosts that received NOD.CD4⁺CD25^- (T reg cell-depleted) polyclonal T cells to prevent lymphopenic-driven proliferation. 24 h later, recipient mice were treated with p31-SP or SHAM-SP. (A) p31-SP therapy induced tolerance and prevented diabetes (_•; n = 4) compared with SHAM-SP control (Ο; n = 3). (B) p31-SP therapy does not induce adaptive T reg cells. Inguinal and pLN cells were stained for FoxP3, CD4, and Vβ4 to enumerate T reg cells to determine if p31-SP therapy generated T reg cells. The average percentage ± SEM of FoxP3⁺Tg⁺CD4⁺ T reg cells is shown from three p31-SP- and three SHAM-SP-treated mice.